Prognostic Factors and a Scoring System for Survival After Radiotherapy for Metastases to the Spinal Column: a Review of 544 Patients at Shizuoka Cancer Center Hospital
Overview
Authors
Affiliations
Background: To optimize selection of a radiotherapy schedule for patients with spinal metastases, the authors analyzed prognostic factors and developed a scoring system to predict survival in such patients.
Methods: Five-hundred forty-four patients with spinal metastases received radiotherapy at Shizuoka Cancer Center Hospital between September 2002 and November 2006. Prognostic factors for survival were studied using a Cox proportional hazards model, and a scoring system was developed based on regression coefficients: Three points were given for an unfavorable tumor type and bad performance status (> or =3); 2 points were given for hypercalcemia, visceral metastases, and previous chemotherapy; and 1 point was given for multiple bone metastases and age > or =71 years.
Results: The overall survival rates after 6 months, 12 months, and 24 months were 49%, 32%, and 19%, respectively, and the median survival was 5.9 months (95% confidence interval, 4.9-6.8 months). In total, 503 patients (93%) were followed for > or =12 months or until death. These patients were separated into Groups A, B, and C based on scores of 0 to 4, 5 to 9, and 10 to 14, respectively. These groups included 24%, 57%, and 19% of patients, respectively; and the mean median survival for Groups A, B, and C was 27.1 months, 5.4 months, and 1.8 months, respectively. Overall survival rates after 6 months, 12 months, and 24 months were 89%, 77%, and 54% in Group A; 46%, 22%, and 9% in Group B; and 7%, 4%, and 0% in Group C, respectively (P < .001).
Conclusions: The scoring system was able to predict the survival of patients with spinal metastases and may be useful for selecting an optimal radiotherapy schedule.
Sharif S, Afsar A, Zileli M, Vaishya S, Gokaslan Z Neurosurg Rev. 2025; 48(1):160.
PMID: 39899191 DOI: 10.1007/s10143-025-03298-3.
Rossi R, Medici F, Habberstad R, Klepstad P, Cilla S, DallAgata M Cancer Med. 2024; 13(19):e70050.
PMID: 39390750 PMC: 11467037. DOI: 10.1002/cam4.70050.
Tam A, Scarpi E, Maltoni M, Rossi R, Fairchild A, Dennis K Cancers (Basel). 2024; 16(9).
PMID: 38730606 PMC: 11083084. DOI: 10.3390/cancers16091654.
Takeda K, Umezawa R, Yamamoto T, Takahashi N, Suzuki Y, Kishida K Rep Pract Oncol Radiother. 2024; 28(5):646-653.
PMID: 38179297 PMC: 10764048. DOI: 10.5603/rpor.97512.
Artificial Intelligence and Predictive Modeling in Spinal Oncology: A Narrative Review.
Kuijten R, Zijlstra H, Groot O, Schwab J Int J Spine Surg. 2023; 17(S1):S45-S56.
PMID: 37164481 PMC: 10318913. DOI: 10.14444/8500.